(1-methoxymethylcyclohexyl)methanol | 956518-76-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (1-methoxymethylcyclohexyl)methanol
• 英文别名: [1-(Methoxymethyl)cyclohexyl]methanol
• CAS: 956518-76-6
• 化学式: C₉H₁₈O₂
• 分子量: 158.241
• InChiKey: FAABVQIBIYGNJV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  29.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  tert-Butyl-(1-methoxymethylcyclohexylmethoxy)diphenylsilane 在 四丁基氟化铵 作用下， 以 四氢呋喃 为溶剂， 反应 18.0h， 生成 (1-methoxymethylcyclohexyl)methanol
  参考文献：
  名称：

  EP2017275

  摘要：

  公开号：

文献信息

• CYCLOPROPYLAMINES AS LSD1 INHIBITORS
  申请人：Incyte Corporation

  公开号：US20150225379A1

  公开（公告）日：2015-08-13

  The present invention is directed to cyclopropylamine derivatives which are LSD1 inhibitors useful in the treatment of diseases such as cancer.

  本发明涉及环丙胺衍生物，这些衍生物是LSD1抑制剂，可用于治疗癌症等疾病。
• APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES
  申请人：AbbVie Inc.

  公开号：US20130096121A1

  公开（公告）日：2013-04-18

  Disclosed are compounds which inhibit the activity of anti-apoptotic Bc1-xL proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bc1-xL protein.

  揭示了抑制抗凋亡Bc1-xL蛋白活性的化合物，含有这些化合物的组合物以及治疗在其中表达抗凋亡Bc1-xL蛋白的疾病的方法。
• Benzisoxazole Compound
  申请人：Sasaki Atsushi

  公开号：US20090318690A1

  公开（公告）日：2009-12-24

  Disclosed is a compound represented by the general formula (I) or a salt thereof: wherein any one of R1, R2 and R3 represents a group represented by the formula: —(CH 2 )m-NR11R12 (wherein m is 1 or 2; and R11 and R12 independently represent a hydrogen atom or a C1-6 alkyl group or may, together with a nitrogen atom to which R11 and R12 are bound, form a 4- or 5-membered cyclic group); the remaining two or R1, R2 and R3 independently represent a group represented by the formula: —(O)n-R21 (wherein n is 0 or 1; and R21 represents a hydrogen atom, a C1-6 alkyl group, a C2-6 alkenyl group, a C2-6 alkynyl group, or the like); and R4 represents a C1-6 alkyl group which may have a substituent or the like.

  本发明涉及一种由通式（I）表示的化合物或其盐：其中R1、R2和R3中的任意一个表示公式表示的基团：—（CH2）m-NR11R12（其中m为1或2；R11和R12独立地表示氢原子或C1-6烷基或可能与R11和R12结合的氮原子一起形成4-或5-成员环状基团）；剩余的两个或R1、R2和R3独立地表示公式表示的基团：—（O）n-R21（其中n为0或1；R21表示氢原子、C1-6烷基、C2-6烯基、C2-6炔基等）；R4表示可能具有取代基的C1-6烷基。
• 2-Aminopyrimidine Derivative
  申请人：Okamoto Yoshinori

  公开号：US20070265289A1

  公开（公告）日：2007-11-15

  The invention relates to a compound useful as remedies or preventives for IKK2-related inflammatory diseases or autoimmune diseases, or that is, a 2-aminopyrimidine derivative having a 2-hydroxyphenyl group at the 6-position thereof and having a saturated cyclic group that contains one nitrogen atom, such as piperidine, at the 4-position thereof. The pharmaceutical composition of the invention and the compound of the invention have an excellent antiinflammatory effect based on the IKK2-inhibitory effect thereof, and are therefore useful for remedies and preventives for inflammatory diseases and autoimmune diseases, especially for rheumatoid arthritis.

  本发明涉及一种化合物，可用作治疗或预防IKK2相关的炎症性疾病或自身免疫性疾病的药物，即在其6位具有2-羟基苯基基团并且在其4位具有含有一个氮原子的饱和环状基团（例如哌啶）的2-氨基嘧啶衍生物。本发明的制药组合物和该化合物具有出色的抗炎作用，基于其IKK2抑制作用，因此对于治疗和预防炎症性疾病和自身免疫性疾病特别是类风湿性关节炎非常有用。
• APOPTOSIS-INDUCED AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES
  申请人：AbbVie Inc.

  公开号：US20160206611A1

  公开（公告）日：2016-07-21

  Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-xL protein.

  本发明涉及一种抑制抗凋亡Bcl-xL蛋白活性的化合物，含有该化合物的组合物以及治疗表达抗凋亡Bcl-xL蛋白的疾病的方法。